Explore how Nvidia’s CEO, Jensen Huang, forecasts a future where AI machines surpass human intelligence within five years.

While trying to slim down a bit for her wedding day, one woman decided to take gray market semaglutide — and it landed her in the emergency room.

That woman, whom Healthline refers to as Amy Jenson to protect her privacy in its report, learned she was nearing prediabetic levels of the hemoglobin A1C at a visit to her naturopathic doctor. The naturopath suggested Jenson try semaglutide, the active ingredient in the Ozempic and Wegovy injectables, to help reach her goal weight and head off full-blown diabetes.

She purchased some semaglutide with B12 shots, which are often sold together in injectable forms from online and in-person pharmacies that operate in a legal grey area, from a compounding facility. She was initially prescribed a low dose that increased by small increments each month.

“The only way to be happy is to do what you love,” Ron Gutman, cofounder of digital health company Intrivo, told Business Insider.

Powner’s team didn’t check whether its sulfur-based catalysts had a chiral bias. That’s where Donna Blackmond, an origin of life chemist at Scripps Research, and her colleagues Min Deng and Jinhan Yu grabbed the baton. They tested two of Powner’s sulfur compounds to see whether the catalysts were sensitive to chirality as they formed dipeptides. They were, but not in the way Blackmond had expected. The catalysts created about four times as many “heterochiral” dipeptides—those pairing a left-handed amino acid (L) with a right-handed (D) one—as fully chiral products. “We thought it was bad news,” Blackmond says, because it suggested that even if amino acids on early Earth started with a bias, it would have been scrambled as proteins formed.

But as Blackmond and her colleagues looked more deeply, the news got better. In a series of experiments, the Scripps researchers started with skewed proportions of L and D amino acids—for example, 60% Ls and 40% Ds. The L, D and D, L heterochiral dipeptides formed most quickly, and as they did they pulled equal numbers of L and D amino acids out of the mix. Because of the baseline bias, eventually a predominance of Ls remained in the pool of unreacted amino acids, raising the likelihood of forming fully lefthanded dipeptides. “It’s like a domino effect,” Powner says. The first heterochiral reaction eventually encourages more homochirals to form. “And it’s a general process that works with all amino acids,” Powner says. Joyce adds: “It’s just math.”

Follow-up experiments suggested a second bias that amplifies the effect. The team found that heterochiral dipeptides precipitate out of a solution more quickly than homochiral ones, speeding the way to a relative abundance of either homochiral L, L or D, D pairs, depending the starting mix. Just why this precipitation bias occurs isn’t yet clear, Blackmond says. However, Joyce says, together with the other effect, “it beautifully fits the [experimental] data.” Blackmond adds: “The wrong answer turned out to be the right answer to get us to homochirality.”

Former CIA agent, CEO and author Rupal Patel reveals the time management strategy that sets her up for success throughout the week.

Humanoid robot maker Figure has announced a new deal with ChatGPT-maker OpenAI.

The company recently closed a $675 million round of funding at a $2.6 billion valuation as well, with notable backers including Amazon founder Jeff Bezos, Microsoft, and AI chipmaker Nvidia.

It’s a notable agreement, especially considering Figure has yet to release a viable commercial product — which highlights just how much momentum there is in the AI space as investors hope for gargantuan growth.

The Artemis II mission is scheduled to put people back into lunar orbit in 2025, while the Artemis III will see humans return to the lunar surface no earlier than 2026, per Space. America’s manned mission to the moon is the marquee news, but the real news here is that the logo we most associate with NASA is called the “worm.” Quick! Put on some Beastie Boys, y’all, because NASA is once again doing the worm.

Artemis II Boosters Receive Iconic NASA “Worm”

The challenges of testing whether AI has rights.

Apple struggled to build its high tech car, burning billions of dollars while constantly changing its project’s direction.

The effort to give robots AI brains is revealing big practical challenges—and bigger ethical concerns.

By David Berreby